

November 10, 2020

Kent Imaging Liz Newell Director, Clinical Research 804B 16th Ave SW Calgary, Alberta t2r 0s9 Canada

Re: K201976

Trade/Device Name: SnapshotNIR Regulation Number: 21 CFR 870.2700

Regulation Name: Oximeter Regulatory Class: Class II Product Code: MUD Dated: July 15, 2020

Received: July 16, 2020

#### Dear Liz Newell:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm</a> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

K201976 - Liz Newell Page 2

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <a href="https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products">https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products</a>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems">https://www.fda.gov/medical-device-problems</a>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance">https://www.fda.gov/training-and-continuing-education/cdrh-learn</a>) and CDRH Learn (<a href="https://www.fda.gov/training-and-continuing-education/cdrh-learn">https://www.fda.gov/training-and-continuing-education/cdrh-learn</a>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</a>) for more information or contact DICE by email (<a href="DICE@fda.hhs.gov">DICE@fda.hhs.gov</a>) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Purva Pandya
Acting Assistant Director
DHT4A: Division of General Surgery Devices
OHT4: Office of Surgical
and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

# DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

# **Indications for Use**

Form Approved: OMB No. 0910-0120

Expiration Date: 06/30/2020 See PRA Statement below.

510(k) Number (if known)
K201976
Device Name SnapshotNIR
Indications for Use (Describe) SnapshotNIR is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports an approximate value of:
<ul><li>oxygen saturation (StO2),</li><li>relative oxyhemogoblin level (HbO2), and</li><li>relative deoxyhemoglobin (Hb) level</li></ul>
in superficial tissue. SnapshotNIR displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions.
SnapshotNIR is indicated for use to determine oxygenation levels in superficial tissues.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

CONTINUE ON A SEPARATE PAGE IF NEEDED.

#### \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

# 510(k) Summary

#### Snapshot<sub>NIR</sub> (November 2<sup>nd</sup>, 2020)

#### **Submittal Information:**

Post-approval contact: Liz Newell Kent Imaging Inc. 804B 16<sup>th</sup> Ave SW Calgary, AB, Canada T2R 0S9

Phone: 403-455-7610 Fax: 877-664-5450

#### **Device Name and Classification**

Proprietary Name: Snapshot<sub>NIR</sub>
Common Name: Tissue Oximeter

Classification Name: Oximeter, Tissue Saturation (21 CFR 870.2700, Product Code: 74 MUD)

Device Class II

Classification Panel: Cardiovascular

### **Device Description**

Snapshot<sub>NIR</sub>, Model KD204 (K201976), is a modification to the Kent Camera, Model KD203 (K163070). The changes made to create the modified snapshot include modifications to the software. Both devices have similar hardware.

Snapshot<sub>NIR</sub> is based on multispectral imaging technology and performs spectral analysis at each point in a two-dimensional scanned area producing an image displaying information derived from the analysis. Snapshot<sub>NIR</sub> determines the approximate values of oxygen saturation ( $S_tO_2$ ), oxyhemoglobin levels (HbO<sub>2</sub>), and deoxyhemoglobin levels (Hb) in superficial tissues and displays a two-dimensional, color-coded image of the tissue oxygenation ( $S_tO_2$ ).

The camera consists of:

Camera: Contains light source, camera and touchscreen PC

Recharger: Used to recharge the camera

Reference Card: To calibrate the camera

#### **Intended Use**

Snapshot<sub>NIR</sub> is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports an approximate value of:

- oxygen saturation (StO<sub>2</sub>),
- oxyhemoglobin level (HbO<sub>2</sub>), and
- deoxyhemoglobin (Hb) level

in superficial tissue. Snapshot $_{\text{NIR}}$  displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions.

The  $Snapshot_{NIR}$  is indicated for use to determine oxygenation levels in superficial tissues.

# **Comparison with the Predicate Device**

Comparative Feature	Kent Imaging Inc. Modified Snapshot <sub>NIR</sub> - KD204 (K201976)	Kent Imaging Inc. Predicate Kent Camera - KD203 (K163070)	Significant Differences
Indications for Use	The Kent Camera is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports an approximate value of oxygen saturation (StO2), oxyhemoglobin level (HbO2), and deoxyhemoglobin (Hb) level in superficial tissue. The Kent Camera displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. The Kent Camera is indicated for use to determine oxygenation levels in superficial tissues.	The Kent Camera is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports an approximate value of oxygen saturation (StO2), oxyhemoglobin level (HbO2), and deoxyhemoglobin (Hb) level in superficial tissue. The Kent Camera displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. The Kent Camera is indicated for use to determine oxygenation levels in superficial tissues.	Same
Measurements	<ul><li>Oxygen saturation</li><li>Oxyhemoglobin level</li><li>Deoxyhemoglobin level</li></ul>	<ul> <li>Oxygen saturation</li> <li>Oxyhemoglobin level</li> <li>Deoxyhemoglobin level</li> </ul>	Same
Method of Measurement	Non-invasive, non- patient contacting imaging head illuminates the surface and receives	Non-invasive, non- patient contacting imaging head illuminates the surface	Same

	returned light	and receives returned light	
	6 wavelengths between 600nm and 1000nm	6 wavelengths between 600nm and 1000nm	Same
	A CMOS image sensor	A CMOS image sensor	Same
	with global shutter is	with global shutter is	Same
	used as the detector	used as the detector	
	Spectral analysis at	Spectral analysis at	Similar –
	specific wavelengths of	specific wavelengths of	improved signal
	light returned from the	light returned from the	to noise in
	target tissue	target tissue	modified device
Light Source	LEDs	LEDs	Same
Lens	Corrected and optimized	Corrected and optimized	Same
20.10	for use from 400nm to	for use from 400nm to	Sus
	1000nm	1000nm	
	Two-dimensional	Two-dimensional	Same
	color-coded map of	color-coded map of	
Output Display	estimated oxygen	estimated oxygen	
	saturation	saturation	
	Numeric data	<ul> <li>Numeric data</li> </ul>	
Power Source	DC (battery-powered)	DC (battery-powered)	Same
Patient Contact	None	None	Same
Control Method	Computer controlled	Computer controlled	Same
			Similar;
			Modified device
	Preformed at start-up by		monitors
	operator and repeated if	Preformed at start-up by	operating
	operating conditions of	operator. Performed	conditions and
Calibration	camera change to the	periodically during	requires
	degree that necessitates	extended picture	recalibration
	recalibration	capturing sessions	based on
			changed
			operating
	Device is not considered	Device is not considered	conditions Same
Sterility	sterile	sterile	Same
Software	Sterne	Sterne	Similar;
Language			Jiiiliai,
- Language			The change in
			programming
			languages had no
	C#	LabVIEW	effect on
			performance.
			This change does
			not present any
			additional safety

			or effectiveness
			concerns.
	Circle (C O 0()		Similar;
Selection Tools	Circle (S <sub>t</sub> O <sub>2</sub> %)		Modified device
	Region/Perimeter (StO <sub>2</sub> % and cm <sup>2</sup> )	Circle (%)	displays
			approximate 2D
	Line (cm)		measures in
			addition to %S <sub>t</sub> O <sub>2</sub>
			Similar; users can
			draw a custom
			region of
			interest.
Region of	Support freehand		
Interest (ROI)	drawing ROI selection	None	The change to
Area	(cm²)		include freehand
			ROI drawing had
			no effect on the
			performance of
			the device.
System	Camera, Calibration card	Camera, Calibration card	Same
Components	and recharger	and recharger	
Image Format	DICOM	DICOM	Same
			Similar; Wi-Fi
			only available
			•
			when emailing
			when emailing reports.
			reports.
			reports.
			_
Connectivity	Wi-Fi available only	Wi-Fi not enabled	reports.  The change to
Connectivity	Wi-Fi available only when emailing a report	Wi-Fi not enabled	reports.  The change to turn on Wi-Fi does not affect
Connectivity	_	Wi-Fi not enabled	reports.  The change to turn on Wi-Fi does not affect the performance
Connectivity	_	Wi-Fi not enabled	reports.  The change to turn on Wi-Fi does not affect the performance of the device and
Connectivity	_	Wi-Fi not enabled	reports.  The change to turn on Wi-Fi does not affect the performance of the device and does not present
Connectivity	_	Wi-Fi not enabled	reports.  The change to turn on Wi-Fi does not affect the performance of the device and does not present any effectiveness
Connectivity	_	Wi-Fi not enabled	reports.  The change to turn on Wi-Fi does not affect the performance of the device and does not present any effectiveness concerns or
Connectivity	_	Wi-Fi not enabled	reports.  The change to turn on Wi-Fi does not affect the performance of the device and does not present any effectiveness
Connectivity	_	Wi-Fi not enabled	reports.  The change to turn on Wi-Fi does not affect the performance of the device and does not present any effectiveness concerns or unacceptable

## **Similarities and Differences**

The changes made to create the modified Snapshot<sub>NIR</sub> are software specific. Both devices have the same hardware (LEDs, image sensor, enclosure) and are the same mechanically. Both cameras use spectral analysis to determine oxygenation levels in near-surface tissues. Both cameras display numeric values of approximate oxygen saturation of the hemoglobin as well as displaying the related approximate oxyhemoglobin and deoxyhemoglobin levels necessary for

the oxygen saturation calculation. Both cameras provide two-dimensional mapping of color-coded oxygenation levels. Both cameras do not come in contact with the patient. Both cameras have the same indications for use and the same fundamental scientific technology.

The modified Snapshot<sub>NIR</sub> has several software specific differences compared to the predicate Kent Camera. Snapshot<sub>NIR</sub> application is written in C# where the predicate device was written in LabVIEW. Snapshot<sub>NIR</sub> has a modified algorithm for calculating S<sub>t</sub>O<sub>2</sub>. The updated algorithm was implemented to increase the signal to noise ratio and provide better image quality is relies on the same fundamental scientific principles as the predicate algorithm. Lastly, Snaphot<sub>NIR</sub> has an updated user interface which allows for freehand selection of areas and approximate 2D size measurements and can be connected to a wireless network. The user follows the same workflow for capturing images with the modified device as with the predicate.

#### **Non-Clinical Tests**

The modified device went through and passed both internal testing for user and design requirements, as did the predicate device. The modified device compared to the predicate device has no change to the hardware or to the fundamental way it interacts with or configures the hardware therefore although testing wasn't repeated, it is still compliant with the international standards below.

- Electrical safety and essential performance: ANSI/AAMI ES60601-1:2005/(R)2012
- Electromagnetic compatibility: IEC 60601-1-2: 2014

Both the predicate and modified devices are battery (DC) powered. The same battery is used in both devices and it is compliant with the following standards:

- Battery safety testing: IEC 62133:2012
- Transportation safety testing of lithium batteries: UN38.3:2009 T

#### **Performance Data**

A pre-clinical study was conducted comparing tissue oxygen hemoglobin saturation ( $S_tO_2$ ) measurements taken with the predicate Kent Camera (KD203) and the modified device (KD204). The agreement study used a forearm ischemia protocol to evaluate the performance of the devices both within the expected normal range of  $S_tO_2$  as well as situations where  $S_tO_2$  is depressed. The forearm ischemia protocol was intended to test the devices over the clinically meaningful dynamic range of  $S_tO_2$ .

The study objectives were as follows:

- Demonstrate the new StO<sub>2</sub> algorithm has superior performance and stability when measuring low reflectivity tissue than the predicate algorithm.
- Demonstrate the linear relationship between the S<sub>t</sub>O<sub>2</sub> measurements from the two devices over a clinically meaningful dynamic range of S<sub>t</sub>O<sub>2</sub>.
- Through the use of Bland-Altman plots quantify any scale shift (slope) and bias (difference in mean values) between the devices and estimate the 95% levels of agreement.

Field data acquired on 38 volunteer subjects undergoing a forearm ischemia – reperfusion challenge confirmed stimulation and lab bench testing that the replacement algorithm provides estimates for relative oxy- [Hbo] and deoxy- [Hb] hemoglobin linearly related to the original (predicate) algorithm R² > 0.98 with RMSE r[Hb] = 0.000239 and RMSE r[Hbo] = 0.00208. These hemoglobin estimates are used to calculate an estimated tissue hemoglobin oxygenation ( $S_tO_2$ ).  $S_tO_2 = r[Hbo] / (r[Hb] + r[Hbo])$ . Linear regression in conjunction with Bland – Altman analysis was used to compare  $S_tO_2$  estimates for the predicate algorithm and the proposed replacement algorithm.

The agreement study concluded that  $S_tO_2$  measurements from the modified device (KD204) and the predicate Kent Camera (KD203) show a linear relationship over a wide and clinically meaningful dynamic range of  $S_tO_2$ . These findings support the use of the modified device (KD204) to non-invasively measure superficial tissue hemoglobin oxygen saturation.

#### **Basis of Substantial Equivalence**

The KD204 (K201976) near infrared imaging device has the same indications for use, similar technology characteristics and principles of operation as the predicate device, KD203 (K163070). The modifications between the KD204 and KD203 do not raise new or different types of questions regarding safety and effectiveness. Non-clinical performance data supports the safety and effectiveness of the KD204 device.

Therefore the KD204 (K201976) is considered substantially equivalence to the KD203 (K23432).